PT - JOURNAL ARTICLE AU - Antúnez-Montes, Omar Yassef AU - Escamilla, Maria Isabel AU - Figueroa-Uribe, Augusto Flavio AU - Arteaga-Menchaca, Erick AU - Lavariega-Saráchaga, Manuel AU - Salcedo-Lozada, Perla AU - Melchior, Priscilla AU - de Oliveira, Rodrigo Beréa AU - Caballero, Juan Carlos Tirado AU - Redondo, Hernando Pinzon AU - Fontalvo, Laura Vanessa Montes AU - Hernandez, Roger AU - Chavez, Carolina AU - Campos, Francisco AU - Uribe, Fadia AU - Aguila, Olguita del AU - Aida, Jorge Alberto Rios AU - Buitrago, Andrea Parra AU - Londoño, Lina Maria Betancur AU - Vega, León Felipe Mendoza AU - Hernández, Carolina Almeida AU - Sali, Michela AU - Palacio, Julian Esteban Higuita AU - Gomez-Vargas, Jessica AU - Yock-Corrales, Adriana AU - Buonsenso, Danilo TI - COVID-19 and Multisystem Inflammatory Syndrome in Latin American children: a multinational study AID - 10.1101/2020.08.29.20184242 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.29.20184242 4099 - http://medrxiv.org/content/early/2020/09/02/2020.08.29.20184242.short 4100 - http://medrxiv.org/content/early/2020/09/02/2020.08.29.20184242.full AB - Background To date, there are no comprehensive data on pediatric COVID-19 from Latin America. This study aims to assess COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) in Latin American children, in order to appropriately plan and allocate resources to face the pandemic on a local and International leverMethods Ambispective multicentre cohort study from five Latin American countries. Children aged 18 years or younger with microbiologically confirmed SARS-CoV-2 infection were included.Findings 409 children were included, with a median age of 53.0 years (IQR 0.6–9.0). Of these, 95 191 (23.2%) were diagnosed with MIS-C. 191 (46.7%) children were admitted to hospital and 52 (12.7%) required admission to a Pediatric Intensive Care Unite (PICU). 92 (22.5%) patients required oxygen support: 8 (2%) were started on continuous positive airway pressure (CPAP) and 29 (7%) on mechanical ventilation. 35 (8.5%) patients required inotropic support. The following factors were associated with PICU admission: pre-existing medical condition (P < 0.0001), immunodeficiency (P = 0.01), lower respiratory tract infection (P< 0.0001), gastrointestinal symptoms (P = 0.006), radiological changes suggestive of pneumonia and acute respiratory distress syndrome (P< 0.0001), low socioeconomic conditions (P 0.009).Conclusions This study shows a generally more severe form of COVID-19 and a high number of MIS-C in Latin American children, compared with studies from China, Europe and North America, and support current evidence of a more severe disease in Latin/Hyspanic children or in people of lower socioeconomic level. The findings highlight an urgent need of more data of COVID-19 in South America.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnothingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the CoviDOMINGO core group and approved by the Ethic Committee of the coordinating center and by each participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-06; Peru: N 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal nor identifiable data were collected during the conduct of this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable upon request